JP2013511486A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013511486A5 JP2013511486A5 JP2012539312A JP2012539312A JP2013511486A5 JP 2013511486 A5 JP2013511486 A5 JP 2013511486A5 JP 2012539312 A JP2012539312 A JP 2012539312A JP 2012539312 A JP2012539312 A JP 2012539312A JP 2013511486 A5 JP2013511486 A5 JP 2013511486A5
- Authority
- JP
- Japan
- Prior art keywords
- dihydro
- azetidin
- enyl
- oxoprop
- naphthyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 33
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 29
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 14
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 12
- -1 3-oxo-3- (3- (2- (thiophen-2-yl) ethoxy) azetidin-1-yl) prop-1-enyl Chemical group 0.000 claims description 10
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000005647 linker group Chemical group 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 241000191967 Staphylococcus aureus Species 0.000 claims 9
- CQQVSXRUVDVVNO-UBNNNTKFSA-N 6-[(e)-3-[3-[(e)-c-methyl-n-propoxycarbonimidoyl]azetidin-1-yl]-3-oxoprop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C1C(C(/C)=N/OCCC)CN1C(=O)\C=C\C1=CN=C(NC(=O)CC2)C2=C1 CQQVSXRUVDVVNO-UBNNNTKFSA-N 0.000 claims 6
- 208000015181 infectious disease Diseases 0.000 claims 6
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims 5
- 230000000813 microbial effect Effects 0.000 claims 5
- IRGSWLRUVQHHTF-VMPITWQZSA-N 6-[(e)-3-[3-(1-benzofuran-2-yl)azetidin-1-yl]-3-oxoprop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C1=CC=C2OC(C3CN(C3)C(\C=C\C=3C=C4CCC(=O)NC4=NC=3)=O)=CC2=C1 IRGSWLRUVQHHTF-VMPITWQZSA-N 0.000 claims 4
- OTHXOQIDEXDBSX-RMKNXTFCSA-N 6-[(e)-3-[3-(3-methyl-1-benzofuran-2-yl)azetidin-1-yl]-3-oxoprop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound N1C(=O)CCC2=CC(/C=C/C(=O)N3CC(C3)C3=C(C4=CC=CC=C4O3)C)=CN=C21 OTHXOQIDEXDBSX-RMKNXTFCSA-N 0.000 claims 4
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims 4
- 229960003085 meticillin Drugs 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 108010059993 Vancomycin Proteins 0.000 claims 3
- 229960003165 vancomycin Drugs 0.000 claims 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 3
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims 3
- IEAWJZJDIUZANC-AATRIKPKSA-N (e)-3-[3-[(dimethylamino)methyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]-1-[3-(thiophen-2-ylmethoxy)azetidin-1-yl]prop-2-en-1-one Chemical compound C1=C2C(CN(C)C)=CNC2=NC=C1\C=C\C(=O)N(C1)CC1OCC1=CC=CS1 IEAWJZJDIUZANC-AATRIKPKSA-N 0.000 claims 2
- PPLOEUSGELSLMK-BQYQJAHWSA-N 1'-methyl-6-[(e)-3-[3-(3-methyl-1-benzofuran-2-yl)azetidin-1-yl]-3-oxoprop-1-enyl]spiro[1,4-dihydro-1,8-naphthyridine-3,4'-piperidine]-2-one Chemical compound C1CN(C)CCC21C(=O)NC1=NC=C(\C=C\C(=O)N3CC(C3)C3=C(C4=CC=CC=C4O3)C)C=C1C2 PPLOEUSGELSLMK-BQYQJAHWSA-N 0.000 claims 2
- VFHWQEBTECYEOD-USGQHZDISA-N 1'-methyl-6-[(e)-3-[3-[(e)-c-methyl-n-phenylmethoxycarbonimidoyl]azetidin-1-yl]-3-oxoprop-1-enyl]spiro[1,4-dihydro-1,8-naphthyridine-3,4'-piperidine]-2-one Chemical compound C1CN(C)CCC21C(=O)NC1=NC=C(\C=C\C(=O)N3CC(C3)C(\C)=N\OCC=3C=CC=CC=3)C=C1C2 VFHWQEBTECYEOD-USGQHZDISA-N 0.000 claims 2
- XEWAXJQCXCRSSU-JHVREWCZSA-N 1'-methyl-6-[(e)-3-[3-[(e)-c-methyl-n-propoxycarbonimidoyl]azetidin-1-yl]-3-oxoprop-1-enyl]spiro[1,4-dihydro-1,8-naphthyridine-3,4'-piperidine]-2-one Chemical compound C1C(C(/C)=N/OCCC)CN1C(=O)\C=C\C1=CN=C(NC(=O)C2(CCN(C)CC2)C2)C2=C1 XEWAXJQCXCRSSU-JHVREWCZSA-N 0.000 claims 2
- NKNFQSGFCHDMGX-SNAWJCMRSA-N 1'-methyl-6-[(e)-3-oxo-3-[3-(2-thiophen-2-ylethoxy)azetidin-1-yl]prop-1-enyl]spiro[1,4-dihydro-1,8-naphthyridine-3,4'-piperidine]-2-one Chemical compound C1CN(C)CCC21C(=O)NC1=NC=C(\C=C\C(=O)N3CC(C3)OCCC=3SC=CC=3)C=C1C2 NKNFQSGFCHDMGX-SNAWJCMRSA-N 0.000 claims 2
- JEMJJOWUMZGZLV-SNAWJCMRSA-N 1'-methyl-6-[(e)-3-oxo-3-[3-(thiophen-2-ylmethoxy)azetidin-1-yl]prop-1-enyl]spiro[1,4-dihydro-1,8-naphthyridine-3,4'-piperidine]-2-one Chemical compound C1CN(C)CCC21C(=O)NC1=NC=C(\C=C\C(=O)N3CC(C3)OCC=3SC=CC=3)C=C1C2 JEMJJOWUMZGZLV-SNAWJCMRSA-N 0.000 claims 2
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 claims 2
- WUULBUPSYVJOJS-SNAWJCMRSA-N 3-[2-(4-methylpiperazin-1-yl)ethyl]-6-[(e)-3-oxo-3-[3-(thiophen-2-ylmethoxy)azetidin-1-yl]prop-1-enyl]-1,4-dihydropyrido[2,3-d]pyrimidin-2-one Chemical compound C1CN(C)CCN1CCN1C(=O)NC2=NC=C(\C=C\C(=O)N3CC(C3)OCC=3SC=CC=3)C=C2C1 WUULBUPSYVJOJS-SNAWJCMRSA-N 0.000 claims 2
- XSYSYTCUZNKYJG-AATRIKPKSA-N 6-[(e)-3-(3-butoxyazetidin-1-yl)-3-oxoprop-1-enyl]-1'-methylspiro[1,4-dihydro-1,8-naphthyridine-3,4'-piperidine]-2-one Chemical compound C1C(OCCCC)CN1C(=O)\C=C\C1=CN=C(NC(=O)C2(CCN(C)CC2)C2)C2=C1 XSYSYTCUZNKYJG-AATRIKPKSA-N 0.000 claims 2
- FPEKLOOAKYGFFC-RMKNXTFCSA-N 6-[(e)-3-(4-hydroxy-4-phenylpiperidin-1-yl)-3-oxoprop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C1CN(C(=O)\C=C\C=2C=C3CCC(=O)NC3=NC=2)CCC1(O)C1=CC=CC=C1 FPEKLOOAKYGFFC-RMKNXTFCSA-N 0.000 claims 2
- KUGSQMJLYWUVGU-GORDUTHDSA-N 6-[(e)-3-(azetidin-1-yl)-3-oxoprop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C=1N=C2NC(=O)CCC2=CC=1/C=C/C(=O)N1CCC1 KUGSQMJLYWUVGU-GORDUTHDSA-N 0.000 claims 2
- CXTHEZRFDLOSGG-DHZHZOJOSA-N 6-[(e)-3-[2-(1,3-benzoxazol-2-yl)piperidin-1-yl]-3-oxoprop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C1=CC=C2OC(C3CCCCN3C(\C=C\C=3C=C4CCC(=O)NC4=NC=3)=O)=NC2=C1 CXTHEZRFDLOSGG-DHZHZOJOSA-N 0.000 claims 2
- SYUUXAROKMQQDY-VMPITWQZSA-N 6-[(e)-3-[2-(5-methyl-1,2,4-oxadiazol-3-yl)piperidin-1-yl]-3-oxoprop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound O1C(C)=NC(C2N(CCCC2)C(=O)\C=C\C=2C=C3CCC(=O)NC3=NC=2)=N1 SYUUXAROKMQQDY-VMPITWQZSA-N 0.000 claims 2
- LFCYAMHFEITVFX-ZZXKWVIFSA-N 6-[(e)-3-[3-(2-methylprop-2-enoxy)azetidin-1-yl]-3-oxoprop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C1C(OCC(=C)C)CN1C(=O)\C=C\C1=CN=C(NC(=O)CC2)C2=C1 LFCYAMHFEITVFX-ZZXKWVIFSA-N 0.000 claims 2
- JCULLUDCSGOFBT-GORDUTHDSA-N 6-[(e)-3-[3-(5-methyl-1,2,4-oxadiazol-3-yl)azetidin-1-yl]-3-oxoprop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound O1C(C)=NC(C2CN(C2)C(=O)\C=C\C=2C=C3CCC(=O)NC3=NC=2)=N1 JCULLUDCSGOFBT-GORDUTHDSA-N 0.000 claims 2
- KMUUZBAIAHTLTC-GORDUTHDSA-N 6-[(e)-3-[3-[(1-methylpyrazol-3-yl)methoxy]azetidin-1-yl]-3-oxoprop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound CN1C=CC(COC2CN(C2)C(=O)\C=C\C=2C=C3CCC(=O)NC3=NC=2)=N1 KMUUZBAIAHTLTC-GORDUTHDSA-N 0.000 claims 2
- MHQJJKSHMWQUPO-GORDUTHDSA-N 6-[(e)-3-[3-[(3-methylthiophen-2-yl)methoxy]azetidin-1-yl]-3-oxoprop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C1=CSC(COC2CN(C2)C(=O)\C=C\C=2C=C3CCC(=O)NC3=NC=2)=C1C MHQJJKSHMWQUPO-GORDUTHDSA-N 0.000 claims 2
- ZIRROQDMKBOMQJ-DAFODLJHSA-N 6-[(e)-3-[3-[(4-bromothiophen-2-yl)methoxy]azetidin-1-yl]-3-oxoprop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound BrC1=CSC(COC2CN(C2)C(=O)\C=C\C=2C=C3CCC(=O)NC3=NC=2)=C1 ZIRROQDMKBOMQJ-DAFODLJHSA-N 0.000 claims 2
- ZZARNBFLZRFGDW-DAFODLJHSA-N 6-[(e)-3-[3-[(4-chlorothiophen-2-yl)methoxy]azetidin-1-yl]-3-oxoprop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound ClC1=CSC(COC2CN(C2)C(=O)\C=C\C=2C=C3CCC(=O)NC3=NC=2)=C1 ZZARNBFLZRFGDW-DAFODLJHSA-N 0.000 claims 2
- DYQOBDOAKVJDIV-XVNBXDOJSA-N 6-[(e)-3-[3-[(5-methylthiophen-2-yl)methoxy]azetidin-1-yl]-3-oxoprop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound S1C(C)=CC=C1COC1CN(C(=O)\C=C\C=2C=C3CCC(=O)NC3=NC=2)C1 DYQOBDOAKVJDIV-XVNBXDOJSA-N 0.000 claims 2
- VGRSOAVDMJUWIS-LHPQVSFSSA-N 6-[(e)-3-[3-[(e)-2-methylbut-2-enoxy]azetidin-1-yl]-3-oxoprop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C1C(OCC(/C)=C/C)CN1C(=O)\C=C\C1=CN=C(NC(=O)CC2)C2=C1 VGRSOAVDMJUWIS-LHPQVSFSSA-N 0.000 claims 2
- QAKGQHANERWTJB-AOGGBPEJSA-N 6-[(e)-3-[3-[(e)-but-2-enoxy]azetidin-1-yl]-3-oxoprop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C1C(OC/C=C/C)CN1C(=O)\C=C\C1=CN=C(NC(=O)CC2)C2=C1 QAKGQHANERWTJB-AOGGBPEJSA-N 0.000 claims 2
- QAKGQHANERWTJB-UDJLOATDSA-N 6-[(e)-3-[3-[(z)-but-2-enoxy]azetidin-1-yl]-3-oxoprop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C1C(OC\C=C/C)CN1C(=O)\C=C\C1=CN=C(NC(=O)CC2)C2=C1 QAKGQHANERWTJB-UDJLOATDSA-N 0.000 claims 2
- NVPQSHFBQKIUEH-LGCJVJRSSA-N 6-[(e)-3-[3-[(z)-n-ethoxy-c-methylcarbonimidoyl]azetidin-1-yl]-3-oxoprop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C1C(C(\C)=N/OCC)CN1C(=O)\C=C\C1=CN=C(NC(=O)CC2)C2=C1 NVPQSHFBQKIUEH-LGCJVJRSSA-N 0.000 claims 2
- WYKRWRKJVRDEPC-DAFODLJHSA-N 6-[(e)-3-[4-(2-hydroxyethyl)piperidin-1-yl]-3-oxoprop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C1CC(CCO)CCN1C(=O)\C=C\C1=CN=C(NC(=O)CC2)C2=C1 WYKRWRKJVRDEPC-DAFODLJHSA-N 0.000 claims 2
- PJZDJQFKDJPICJ-LZCJLJQNSA-N 6-[(e)-3-[4-[(4-fluorophenoxy)methyl]piperidin-1-yl]-3-oxoprop-1-enyl]-2-oxo-1h-1,8-naphthyridine-3-carboxamide Chemical compound C=1N=C2NC(=O)C(C(=O)N)=CC2=CC=1\C=C\C(=O)N(CC1)CCC1COC1=CC=C(F)C=C1 PJZDJQFKDJPICJ-LZCJLJQNSA-N 0.000 claims 2
- XRTUEMFKRZPEGQ-LZCJLJQNSA-N 6-[(e)-3-[4-[(4-fluorophenoxy)methyl]piperidin-1-yl]-3-oxoprop-1-enyl]-2-oxo-3,4-dihydro-1h-1,8-naphthyridine-3-carboxamide Chemical compound C=1N=C2NC(=O)C(C(=O)N)CC2=CC=1\C=C\C(=O)N(CC1)CCC1COC1=CC=C(F)C=C1 XRTUEMFKRZPEGQ-LZCJLJQNSA-N 0.000 claims 2
- FHLCDKAROOLURZ-LZCJLJQNSA-N 6-[(e)-3-[4-[(4-fluorophenoxy)methyl]piperidin-1-yl]-3-oxoprop-1-enyl]-3-(hydroxymethyl)-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C=1N=C2NC(=O)C(CO)CC2=CC=1\C=C\C(=O)N(CC1)CCC1COC1=CC=C(F)C=C1 FHLCDKAROOLURZ-LZCJLJQNSA-N 0.000 claims 2
- ZGGLXSGTNJGICQ-DHZHZOJOSA-N 6-[(e)-3-oxo-3-(2-phenylpyrrolidin-1-yl)prop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C=1N=C2NC(=O)CCC2=CC=1/C=C/C(=O)N1CCCC1C1=CC=CC=C1 ZGGLXSGTNJGICQ-DHZHZOJOSA-N 0.000 claims 2
- JGWYJIPGJZUQTP-VMPITWQZSA-N 6-[(e)-3-oxo-3-(3-pentoxyazetidin-1-yl)prop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C1C(OCCCCC)CN1C(=O)\C=C\C1=CN=C(NC(=O)CC2)C2=C1 JGWYJIPGJZUQTP-VMPITWQZSA-N 0.000 claims 2
- XLPKMGVYSWAPAJ-RMKNXTFCSA-N 6-[(e)-3-oxo-3-(3-phenoxyazetidin-1-yl)prop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C=1N=C2NC(=O)CCC2=CC=1/C=C/C(=O)N(C1)CC1OC1=CC=CC=C1 XLPKMGVYSWAPAJ-RMKNXTFCSA-N 0.000 claims 2
- MIUDHBYEEHQKIE-RMKNXTFCSA-N 6-[(e)-3-oxo-3-(3-phenoxypyrrolidin-1-yl)prop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C=1N=C2NC(=O)CCC2=CC=1/C=C/C(=O)N(C1)CCC1OC1=CC=CC=C1 MIUDHBYEEHQKIE-RMKNXTFCSA-N 0.000 claims 2
- IUDCXSXORCOVKT-ZZXKWVIFSA-N 6-[(e)-3-oxo-3-(3-pyridin-3-yloxypyrrolidin-1-yl)prop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C=1N=C2NC(=O)CCC2=CC=1/C=C/C(=O)N(C1)CCC1OC1=CC=CN=C1 IUDCXSXORCOVKT-ZZXKWVIFSA-N 0.000 claims 2
- SNXFJGDLNWCNJI-QPJJXVBHSA-N 6-[(e)-3-oxo-3-(4-propylpiperidin-1-yl)prop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C1CC(CCC)CCN1C(=O)\C=C\C1=CN=C(NC(=O)CC2)C2=C1 SNXFJGDLNWCNJI-QPJJXVBHSA-N 0.000 claims 2
- KISSQSDZTGAZSH-DAFODLJHSA-N 6-[(e)-3-oxo-3-[3-(1,3-thiazol-2-ylmethoxy)azetidin-1-yl]prop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C=1N=C2NC(=O)CCC2=CC=1/C=C/C(=O)N(C1)CC1OCC1=NC=CS1 KISSQSDZTGAZSH-DAFODLJHSA-N 0.000 claims 2
- WMRHMMUTJPJVQF-DAFODLJHSA-N 6-[(e)-3-oxo-3-[3-(3,3,3-trifluoropropoxy)azetidin-1-yl]prop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C1C(OCCC(F)(F)F)CN1C(=O)\C=C\C1=CN=C(NC(=O)CC2)C2=C1 WMRHMMUTJPJVQF-DAFODLJHSA-N 0.000 claims 2
- GPCLMQRZYYYQLI-VMPITWQZSA-N 6-[(e)-3-oxo-3-[3-(3-thiophen-2-ylpropoxy)azetidin-1-yl]prop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C=1N=C2NC(=O)CCC2=CC=1/C=C/C(=O)N(C1)CC1OCCCC1=CC=CS1 GPCLMQRZYYYQLI-VMPITWQZSA-N 0.000 claims 2
- HMQPTXWWOPSKRZ-GORDUTHDSA-N 6-[(e)-3-oxo-3-[3-(4,4,4-trifluorobutoxy)azetidin-1-yl]prop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C1C(OCCCC(F)(F)F)CN1C(=O)\C=C\C1=CN=C(NC(=O)CC2)C2=C1 HMQPTXWWOPSKRZ-GORDUTHDSA-N 0.000 claims 2
- QATPMNXCDSKNPZ-ZZXKWVIFSA-N 6-[(e)-3-oxo-3-[3-(thiophen-2-ylmethoxy)azetidin-1-yl]prop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C=1N=C2NC(=O)CCC2=CC=1/C=C/C(=O)N(C1)CC1OCC1=CC=CS1 QATPMNXCDSKNPZ-ZZXKWVIFSA-N 0.000 claims 2
- GQMLYNXCQKUYTD-MFZKSGLQSA-N 6-[(e)-3-oxo-3-[3-[(e)-1-pyrimidin-2-ylpropan-2-ylideneamino]oxyazetidin-1-yl]prop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C1N(C(=O)\C=C\C=2C=C3CCC(=O)NC3=NC=2)CC1O\N=C(/C)CC1=NC=CC=N1 GQMLYNXCQKUYTD-MFZKSGLQSA-N 0.000 claims 2
- WGWUWXYHWXPSCP-QPJJXVBHSA-N 6-[(e)-3-oxo-3-piperidin-1-ylprop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C=1N=C2NC(=O)CCC2=CC=1/C=C/C(=O)N1CCCCC1 WGWUWXYHWXPSCP-QPJJXVBHSA-N 0.000 claims 2
- WZFFTNBBSJVUDW-ZZXKWVIFSA-N 6-[(e)-3-oxo-3-pyrrolidin-1-ylprop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C=1N=C2NC(=O)CCC2=CC=1/C=C/C(=O)N1CCCC1 WZFFTNBBSJVUDW-ZZXKWVIFSA-N 0.000 claims 2
- AAWFCVXAWCTPJX-UHFFFAOYSA-N 6-[3-[3-[(4-methylthiophen-2-yl)methoxy]azetidin-1-yl]-3-oxoprop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound CC1=CSC(COC2CN(C2)C(=O)C=CC=2C=C3CCC(=O)NC3=NC=2)=C1 AAWFCVXAWCTPJX-UHFFFAOYSA-N 0.000 claims 2
- SIIWVGRQAAYYBW-ONEGZZNKSA-N 7-[(e)-3-oxo-3-[3-(thiophen-2-ylmethoxy)azetidin-1-yl]prop-1-enyl]-1,3,4,5-tetrahydropyrido[2,3-e][1,4]diazepin-2-one Chemical compound C=1N=C2NC(=O)CNCC2=CC=1/C=C/C(=O)N(C1)CC1OCC1=CC=CS1 SIIWVGRQAAYYBW-ONEGZZNKSA-N 0.000 claims 2
- 241000590002 Helicobacter pylori Species 0.000 claims 2
- 241000588747 Klebsiella pneumoniae Species 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- CMEQOKFPTCOYOX-UHFFFAOYSA-N O=C(C=CC(CC1=CC=CN=C1N1)C1=O)N(C1)CC1C1=COC2=C1C=CC=C2 Chemical compound O=C(C=CC(CC1=CC=CN=C1N1)C1=O)N(C1)CC1C1=COC2=C1C=CC=C2 CMEQOKFPTCOYOX-UHFFFAOYSA-N 0.000 claims 2
- AJLRYGIHUNUBKA-UHFFFAOYSA-N O=C(C=CC(CC1=CC=CN=C1N1)C1=O)N(C1)CC1OC1=CC=CC2=C1OC=C2 Chemical compound O=C(C=CC(CC1=CC=CN=C1N1)C1=O)N(C1)CC1OC1=CC=CC2=C1OC=C2 AJLRYGIHUNUBKA-UHFFFAOYSA-N 0.000 claims 2
- YIQJRDZMPFDCCI-UHFFFAOYSA-N O=C(C=CC(CC1=CC=CN=C1N1)C1=O)N(C1)CC1OCC1=CC=CO1 Chemical compound O=C(C=CC(CC1=CC=CN=C1N1)C1=O)N(C1)CC1OCC1=CC=CO1 YIQJRDZMPFDCCI-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000005605 benzo group Chemical group 0.000 claims 2
- LPWJPETURXRRBE-AATRIKPKSA-N ethyl 2-[2-oxo-6-[(e)-3-oxo-3-[3-(thiophen-2-ylmethoxy)azetidin-1-yl]prop-1-enyl]-1,4-dihydropyrido[2,3-d]pyrimidin-3-yl]acetate Chemical compound C=1N=C2NC(=O)N(CC(=O)OCC)CC2=CC=1\C=C\C(=O)N(C1)CC1OCC1=CC=CS1 LPWJPETURXRRBE-AATRIKPKSA-N 0.000 claims 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 2
- 229940037467 helicobacter pylori Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- SBFXWSFMQLMVAN-FARCUNLSSA-N methyl 6-[(e)-3-[4-[(4-fluorophenoxy)methyl]piperidin-1-yl]-3-oxoprop-1-enyl]-2-oxo-3,4-dihydro-1h-1,8-naphthyridine-3-carboxylate Chemical compound C=1N=C2NC(=O)C(C(=O)OC)CC2=CC=1\C=C\C(=O)N(CC1)CCC1COC1=CC=C(F)C=C1 SBFXWSFMQLMVAN-FARCUNLSSA-N 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- DQRVPQOECHQEIS-QPJJXVBHSA-N 6-[(e)-3-(3-butoxyazetidin-1-yl)-3-oxoprop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C1C(OCCCC)CN1C(=O)\C=C\C1=CN=C(NC(=O)CC2)C2=C1 DQRVPQOECHQEIS-QPJJXVBHSA-N 0.000 claims 1
- HCJAKVQPQLYNNM-ZZXKWVIFSA-N 6-[(e)-3-[3-(2-methylpropoxy)azetidin-1-yl]-3-oxoprop-1-enyl]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C1C(OCC(C)C)CN1C(=O)\C=C\C1=CN=C(NC(=O)CC2)C2=C1 HCJAKVQPQLYNNM-ZZXKWVIFSA-N 0.000 claims 1
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 claims 1
- 241000193738 Bacillus anthracis Species 0.000 claims 1
- 241000588779 Bordetella bronchiseptica Species 0.000 claims 1
- SSUFDOMYCBCHML-UHFFFAOYSA-N CCCCC[S](=O)=O Chemical group CCCCC[S](=O)=O SSUFDOMYCBCHML-UHFFFAOYSA-N 0.000 claims 1
- 241001647372 Chlamydia pneumoniae Species 0.000 claims 1
- 241000606768 Haemophilus influenzae Species 0.000 claims 1
- 241001293418 Mannheimia haemolytica Species 0.000 claims 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 1
- 241000588650 Neisseria meningitidis Species 0.000 claims 1
- 241000606856 Pasteurella multocida Species 0.000 claims 1
- 241000223960 Plasmodium falciparum Species 0.000 claims 1
- 241000191980 Staphylococcus intermedius Species 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 229940065181 bacillus anthracis Drugs 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940047650 haemophilus influenzae Drugs 0.000 claims 1
- 229940045505 klebsiella pneumoniae Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 244000000010 microbial pathogen Species 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 0 CC(C)(*)*N(C)C(C=C*)=O Chemical compound CC(C)(*)*N(C)C(C=C*)=O 0.000 description 10
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- DNRADLIRYSUPBP-VQKLYYOLSA-N CC(C)C(N[C@@](C)(NC)OC)N/C=C/C Chemical compound CC(C)C(N[C@@](C)(NC)OC)N/C=C/C DNRADLIRYSUPBP-VQKLYYOLSA-N 0.000 description 1
- HXEYKXZPVSESPD-LSDHHAIUSA-N CC(C)[C@]1(N2)NCC=C(C)C=C1CN(C)[C@@]2(C)OC Chemical compound CC(C)[C@]1(N2)NCC=C(C)C=C1CN(C)[C@@]2(C)OC HXEYKXZPVSESPD-LSDHHAIUSA-N 0.000 description 1
- NWDMKTXAYGPRMX-UHFFFAOYSA-N CCCC(CCC)(Cc1c(N2)ncc(C)c1)C2=O Chemical compound CCCC(CCC)(Cc1c(N2)ncc(C)c1)C2=O NWDMKTXAYGPRMX-UHFFFAOYSA-N 0.000 description 1
- BQVYQFYXSFGMRY-UHFFFAOYSA-N Cc(cc1C=N2)cnc1NC2=O Chemical compound Cc(cc1C=N2)cnc1NC2=O BQVYQFYXSFGMRY-UHFFFAOYSA-N 0.000 description 1
- DOUPPJVYPYJANN-WZUFQYTHSA-N Cc1cc(/C=N\N)c(C)nc1 Chemical compound Cc1cc(/C=N\N)c(C)nc1 DOUPPJVYPYJANN-WZUFQYTHSA-N 0.000 description 1
- DJCJHFFRHKGOCQ-UHFFFAOYSA-N Cc1cnc2[nH]ccc2c1 Chemical compound Cc1cnc2[nH]ccc2c1 DJCJHFFRHKGOCQ-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26230909P | 2009-11-18 | 2009-11-18 | |
| US61/262,309 | 2009-11-18 | ||
| PCT/EP2010/067647 WO2011061214A1 (en) | 2009-11-18 | 2010-11-17 | Novel heterocyclic acrylamides and their use as pharmaceuticals |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013511486A JP2013511486A (ja) | 2013-04-04 |
| JP2013511486A5 true JP2013511486A5 (enExample) | 2015-06-18 |
| JP5816629B2 JP5816629B2 (ja) | 2015-11-18 |
Family
ID=44059228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012539312A Expired - Fee Related JP5816629B2 (ja) | 2009-11-18 | 2010-11-17 | 新規の複素環式アクリルアミド及び医薬としてのその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US8846711B2 (enExample) |
| EP (1) | EP2501693B1 (enExample) |
| JP (1) | JP5816629B2 (enExample) |
| KR (1) | KR20130010456A (enExample) |
| CN (1) | CN102656158B (enExample) |
| AU (1) | AU2010320963B2 (enExample) |
| BR (1) | BR112012011793A2 (enExample) |
| CA (1) | CA2776849A1 (enExample) |
| DK (1) | DK2501693T3 (enExample) |
| ES (1) | ES2526567T3 (enExample) |
| IL (1) | IL218934A0 (enExample) |
| MX (1) | MX2012005759A (enExample) |
| NZ (1) | NZ599444A (enExample) |
| PL (1) | PL2501693T3 (enExample) |
| WO (1) | WO2011061214A1 (enExample) |
| ZA (1) | ZA201202489B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2687533B1 (en) | 2006-07-20 | 2017-07-19 | Debiopharm International SA | Acrylamide derivatives as FAB I inhibitors |
| JP5816629B2 (ja) | 2009-11-18 | 2015-11-18 | ファブ ファーマ エスエーエス | 新規の複素環式アクリルアミド及び医薬としてのその使用 |
| EP2742047B1 (en) * | 2011-08-10 | 2021-05-12 | Janssen Sciences Ireland Unlimited Company | Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones |
| KR101996866B1 (ko) * | 2011-08-10 | 2019-07-05 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 항균성 호모피페리디닐 치환 3,4-디하이드로-1h-[1,8]나프티리디논 |
| JO3611B1 (ar) * | 2011-08-10 | 2020-08-27 | Janssen Sciences Ireland Uc | سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم |
| EP2758376A4 (en) | 2011-09-19 | 2015-04-29 | Vitas Pharma Res Private Ltd | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FATTY ACID BIOSYNTHESIS FOR BACTERIAL INFECTIONS |
| WO2013080222A1 (en) * | 2011-12-02 | 2013-06-06 | Aurigene Discovery Technologies Limited | Substituted pyridine derivatives as fabi inhibitors |
| US9062075B2 (en) | 2011-12-02 | 2015-06-23 | Aurigene Discovery Technologies Limited | Tetrahydropyridine derivatives as FabI inhibitors |
| TWI598099B (zh) * | 2012-04-30 | 2017-09-11 | 健生科學愛爾蘭無限公司 | 新化合物及其新用途 |
| SMT201900411T1 (it) * | 2012-06-19 | 2019-09-09 | Debiopharm Int Sa | Derivati di profaramci di (e)-n-metil-n-((3-metilbenzofuran-2-il)metil -3-(7-osso-5,6,7,8-tetraidro-1,8-naftiridin-3-il)acrilammide |
| US9296760B2 (en) | 2012-08-10 | 2016-03-29 | Janssen Sciences Ireland Uc | Antibacterial compounds |
| US9315522B2 (en) | 2012-08-10 | 2016-04-19 | Janssen Sciences Ireland Uc | Antibacterial compounds |
| WO2014072930A2 (en) * | 2012-11-09 | 2014-05-15 | Aurigene Discovery Technologies Limited | Fused pyridine derivatives as antibacterial agents |
| WO2014195844A1 (en) * | 2013-06-04 | 2014-12-11 | Aurigene Discovery Technologies Limited | TETRAHYDROPYRIDINE DERIVATIVES AS FabI INHIBITORS |
| CN104292142B (zh) * | 2013-07-17 | 2019-05-14 | 天津大地康和医药技术有限公司 | 一种n-芳基杂环丁烷脱芳基方法 |
| WO2015071780A1 (en) * | 2013-11-12 | 2015-05-21 | Aurigene Discovery Technologies Limited | Alkylidine substituted heterocyclyl derivatives as anti-bacterial agents |
| CN104529854B (zh) * | 2015-01-14 | 2016-10-05 | 武汉金联药业有限公司 | 一种取代氮杂环丁烷类医药中间体化合物的合成方法 |
| JP2018525350A (ja) | 2015-07-02 | 2018-09-06 | ホライズン オルファン エルエルシー | Ａｄｏ耐性システアミン類似体およびその使用 |
| BR122023021456A2 (pt) | 2016-02-26 | 2024-02-20 | Debiopharm International S.A. | Uso de di-hidrogeno fosfato de {6- [(e)-3-{metil[(3-metil-1-benfofuran-2- iol)metil]amino)-3- oxopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)- il}metila para tratamento de osteomielite do pé diabético e composição farmacêutica |
| CN108440523A (zh) * | 2018-04-23 | 2018-08-24 | 爱斯特（成都）生物制药股份有限公司 | 一种合成6-溴-3,4-二氢-1h-[1,8]萘啶-2-酮的新方法 |
| FI3923914T3 (fi) | 2019-02-14 | 2023-04-27 | Debiopharm Int Sa | Afabisiiniformulaatio, menetelmä sen valmistamiseksi |
| MA56184A (fr) | 2019-06-14 | 2022-04-20 | Debiopharm Int Sa | Afabicine pour utilisation dans le traitement d'infections bactériennes impliquant un biofilm |
| CN114351128B (zh) * | 2021-12-10 | 2022-12-13 | 江阴纳力新材料科技有限公司 | 镀铜液添加剂、镀铜液、镀铜薄膜及其制备方法、负极集流体、锂电池 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1020864C (zh) * | 1988-09-14 | 1993-05-26 | 中国科学院上海有机化学研究所 | 醛的烯基化反应的催化剂及其应用 |
| TW224042B (enExample) | 1992-04-04 | 1994-05-21 | Basf Ag | |
| CA2220231A1 (en) | 1996-03-15 | 1997-09-18 | Ss Pharmaceutical Co., Ltd. | Novel pyridine derivative and medicament containing the same as an effective ingredient |
| PT923555E (pt) * | 1996-05-01 | 2005-09-30 | Ortho Mcneil Pharm Inc | Derivados carboxamida de pirrolidina, piperidina e hexa-hidroazepina para o tratamento de disturbios tromboticos |
| AR025976A1 (es) | 1999-10-08 | 2002-12-26 | Affinium Pharm Inc | Inhibidores de fab i. |
| CA2444597A1 (en) | 2001-04-06 | 2002-10-06 | Affinium Pharmaceuticals, Inc. | Fab i inhibitors |
| JP2004099499A (ja) * | 2002-09-09 | 2004-04-02 | Sanei Gen Ffi Inc | 抗微生物剤 |
| CA2508792C (en) | 2002-12-06 | 2013-02-05 | Affinium Pharmaceuticals, Inc. | Heterocyclic compounds, methods of making them and their use in therapy |
| CA2568914C (en) | 2004-06-04 | 2013-09-24 | Affinium Pharmaceuticals, Inc. | Therapeutic agents, and methods of making and using the same |
| US20090088433A1 (en) * | 2005-01-26 | 2009-04-02 | Bertrand Leblond | Methods of using as analgesics 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds |
| EP1973902A2 (en) | 2005-12-05 | 2008-10-01 | Affinium Pharmaceuticals, Inc. | 3-heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents |
| WO2007086584A1 (ja) * | 2006-01-30 | 2007-08-02 | Meiji Seika Kaisha, Ltd. | 新規ＦａｂＫおよびＦａｂＩ／Ｋ阻害剤 |
| EP1845087A1 (en) | 2006-04-14 | 2007-10-17 | Mutabilis SA | Hydroxyphenyl derivatives and biological applications thereof |
| EP2687533B1 (en) | 2006-07-20 | 2017-07-19 | Debiopharm International SA | Acrylamide derivatives as FAB I inhibitors |
| EP1942104A1 (en) | 2006-12-20 | 2008-07-09 | sanofi-aventis | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals |
| EP1939180A1 (en) * | 2006-12-20 | 2008-07-02 | sanofi-aventis | Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase |
| US8263613B2 (en) | 2007-02-16 | 2012-09-11 | Affinium Pharmaceuticals, Inc. | Salts, prodrugs and polymorphs of fab I inhibitors |
| WO2009110002A1 (en) * | 2008-03-05 | 2009-09-11 | Council Of Scientific & Industrial Research | Novel efflux pump inhibitors |
| JP2012102018A (ja) * | 2009-03-03 | 2012-05-31 | Astellas Pharma Inc | アミド化合物 |
| JP5816629B2 (ja) | 2009-11-18 | 2015-11-18 | ファブ ファーマ エスエーエス | 新規の複素環式アクリルアミド及び医薬としてのその使用 |
-
2010
- 2010-11-17 JP JP2012539312A patent/JP5816629B2/ja not_active Expired - Fee Related
- 2010-11-17 AU AU2010320963A patent/AU2010320963B2/en not_active Ceased
- 2010-11-17 ES ES10776385.6T patent/ES2526567T3/es active Active
- 2010-11-17 CN CN201080051981.2A patent/CN102656158B/zh not_active Expired - Fee Related
- 2010-11-17 KR KR1020127011047A patent/KR20130010456A/ko not_active Ceased
- 2010-11-17 EP EP10776385.6A patent/EP2501693B1/en not_active Not-in-force
- 2010-11-17 PL PL10776385T patent/PL2501693T3/pl unknown
- 2010-11-17 BR BR112012011793A patent/BR112012011793A2/pt not_active IP Right Cessation
- 2010-11-17 CA CA2776849A patent/CA2776849A1/en not_active Abandoned
- 2010-11-17 MX MX2012005759A patent/MX2012005759A/es active IP Right Grant
- 2010-11-17 DK DK10776385.6T patent/DK2501693T3/en active
- 2010-11-17 NZ NZ599444A patent/NZ599444A/en not_active IP Right Cessation
- 2010-11-17 WO PCT/EP2010/067647 patent/WO2011061214A1/en not_active Ceased
- 2010-11-17 US US13/510,564 patent/US8846711B2/en not_active Expired - Fee Related
-
2012
- 2012-03-29 IL IL218934A patent/IL218934A0/en unknown
- 2012-04-04 ZA ZA2012/02489A patent/ZA201202489B/en unknown
-
2014
- 2014-08-20 US US14/463,994 patent/US9051321B2/en not_active Expired - Fee Related
-
2015
- 2015-05-04 US US14/703,004 patent/US9321769B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2501693T3 (en) | Aza-heterocyclic acrylamides and their use as bactericides | |
| AU2009278442B2 (en) | Imidazopyridin-2-one Derivatives | |
| US9809590B2 (en) | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | |
| Emami et al. | Quinolones: recent structural and clinical developments | |
| US10150783B2 (en) | Heterocyclic ITK inhibitors for treating inflammation and cancer | |
| KR20140097118A (ko) | 항균 화합물 및 이의 사용 방법 | |
| JP2024529347A5 (enExample) | ||
| JP2021107414A (ja) | コロニー刺激因子−１受容体（ｃｓｆ−１ｒ）阻害剤 | |
| JP2014503544A5 (enExample) | ||
| JP2011527684A5 (enExample) | ||
| RU2014112931A (ru) | Пиразолохинолиновое производное | |
| JP2014513139A5 (enExample) | ||
| JP2013531684A5 (enExample) | ||
| JP2011506417A5 (enExample) | ||
| JP2020514267A5 (enExample) | ||
| WO2016015604A1 (en) | Compounds as cdk small-molecule inhibitors and uses thereof | |
| JP2014525420A5 (enExample) | ||
| JP2013537210A5 (enExample) | ||
| JP2011522866A5 (enExample) | ||
| JP2017510576A5 (enExample) | ||
| JP2014522855A5 (enExample) | ||
| JP2009503024A5 (enExample) | ||
| US9839642B2 (en) | Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors | |
| JP2012528137A5 (enExample) | ||
| JP2016509056A (ja) | Ｐｉ３キナーゼモジュレータとしてのヘテロ芳香族化合物、及びその使用方法 |